Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 11:20PM GMT
Release Date Price: $34.49 (+12.79%)
Unidentified Analyst

Good evening, everyone, and thank you for joining us. So today, we're delighted to be hosting Helen from Halozyme.

Questions & Answers

Unidentified Analyst

And just wanted to go ahead and kick off with the first question. For an opportunity for Helen to speak at a high level about the business operations and driving growth through pipeline candidates that you've laid out and through portfolio diversification, through business development, I would love if you could talk about the business and give us a broad overview.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Yes. Thanks for this opportunity. So Halozyme is a profitable biotech company. We are focused on bringing forward disruptive solutions that can improve the treatment experience and potentially also improve outcomes. We do this through 2 drug delivery technologies that's focused on subcutaneous delivery, and we also have a specialty pharmaceutical business as well.

When we think about our drug delivery

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot